M&G PLC Has $41.17 Million Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

M&G PLC trimmed its holdings in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 29.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,721 shares of the company’s stock after selling 49,481 shares during the period. M&G PLC owned 0.11% of BeOne Medicines worth $41,166,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. PNC Financial Services Group Inc. increased its stake in shares of BeOne Medicines by 40.3% in the third quarter. PNC Financial Services Group Inc. now owns 1,319 shares of the company’s stock valued at $449,000 after buying an additional 379 shares in the last quarter. Cibc World Market Inc. acquired a new stake in BeOne Medicines in the 3rd quarter valued at about $255,000. Profund Advisors LLC raised its stake in shares of BeOne Medicines by 23.0% in the third quarter. Profund Advisors LLC now owns 5,831 shares of the company’s stock worth $1,987,000 after acquiring an additional 1,091 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of BeOne Medicines by 7.2% during the third quarter. Oppenheimer Asset Management Inc. now owns 31,674 shares of the company’s stock worth $10,791,000 after purchasing an additional 2,137 shares in the last quarter. Finally, Prasad Wealth Partners LLC bought a new stake in shares of BeOne Medicines during the third quarter valued at approximately $517,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Price Performance

Shares of ONC opened at $346.07 on Monday. The stock has a market cap of $37.95 billion, a P/E ratio of 678.57 and a beta of 0.52. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $196.45 and a 1 year high of $385.22. The stock’s 50-day moving average price is $329.70 and its two-hundred day moving average price is $327.17. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03.

Insider Activity at BeOne Medicines

In other news, SVP Chan Henry Lee sold 1,660 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,627 shares of the firm’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $340.90, for a total value of $895,544.30. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 105,283 shares of company stock worth $32,463,041. 6.62% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ONC shares. Jefferies Financial Group restated a “buy” rating and issued a $420.00 price objective on shares of BeOne Medicines in a research report on Monday, November 17th. Morgan Stanley restated an “overweight” rating and set a $405.00 target price on shares of BeOne Medicines in a research report on Thursday, January 8th. Sanford C. Bernstein upgraded BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target on the stock in a report on Monday, January 12th. Zacks Research cut BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Finally, Citizens Jmp upped their target price on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $379.07.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.